Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 30Neoplasm Metastasis 3Metastatic Hormone-sensitive Prostate Cancer (mHSPC) 2Metastatic Castration-resistant Prostate Cancer 2Urologic Diseases 1Urogenital Neoplasms 1Triple Negative Breast Neoplasms 1Radiation Injuries 1Prostatic Diseases 1Prostate Cancer Metastatic 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Oligometastatic Prostate Cancer 1Neoplasm Recurrence, Local 1Metastatic Hormone Sensitive Prostate Cancer 1Metastatic Castrate-sensitive Prostate Cancer 1Hormone Sensitive Prostate Cancer 1Genital Neoplasms, Male 1Gastrointestinal Diseases 1Breast Neoplasms 1Adenocarcinoma 1

Interventions

Oxaliplatin 9Capecitabine 9Fluorouracil 7pembrolizumab 6Paclitaxel 6Leucovorin 6Cisplatin 5zolbetuximab 4trastuzumab deruxtecan 3enzalutamide 3durvalumab 3cemiplimab 3Trastuzumab 3Gemcitabine 3Docetaxel 3fludarabine 2darolutamide 2Taxes 2Ramucirumab 2Radiotherapy, Image-Guided 2Radiosurgery 2Pemetrexed 2Nivolumab 2Irinotecan 2Cyclophosphamide 2Carboplatin 2Albumin-Bound Paclitaxel 2130-nm albumin-bound paclitaxel 2vistusertib 1tucatinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Adenocarcinoma × Androgen Antagonists × 90 days × Clear all
NCT07426055 2026-03-23

PRO-BOOST-LC

Affidea Nu-med Center of Oncological DIagnostics and Therapy

Phase 2/3 Recruiting
1,200 enrolled
Genitourinary

Adenocarcinoma, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡